Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized double-blind placebo-controlled study of astegolimab in COPD
MOH_2021-11-18_010413Phase 2Not yet recruiting
- Sponsor
- Genentech
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of astegolimab in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Genentech. Primary endpoint: Annualized rate of moderate to severe COPD exacerbations. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
astegolimab
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on MOH_2021-11-18_010413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-11-18_010413.